AtheroGenics announced on Friday that it would halt the use of the high dose of the experimental anti-inflammatory AGI-1067 in a clinical trial after scrutinizing the data on liver-related side effects. Studies of the 75 mg and 150 mg doses will continue. Earlier this year AtheroGenics announced layoffs after AstraZeneca dumped its $1 billion development pact for the drug after AGI-1067 failed studies as a treatment for heart disease.
- see this release
- check out the AP report on the trial
Failed AtheroGenics drug may work as diabetes therapy. Report
AtheroGenics extends waiting period on drug data. Report
Speculation heats up on fate of AGI-1067. Report
AtheroGenics inks billion-dollar licensing deal. Report